Enter your Email Address


Useful Links

Know What The Insiders Are Doing!
Stock Trading Software

More Links




[Most Recent Quotes from www.kitco.com]

[Most Recent Quotes from www.kitco.com]




PetMed In-Line with Zacks – Analyst Blog

Zacks Market Commentaries (October 21st, 2009) Writes:
PetMed Express, Inc. (PETS), the America ’s largest Pet Pharmacy, recently reported second-quarter 2010 results. The quarterly earnings of 28 cents a share came in line with the Zacks Consensus Estimate but rose 12% year-on-year from 25 cents posted in the prior-year quarter.  Net sales climbed 5% to $62.4 million during the quarter. Reorder sales jumped 11% to $45.8 million, whereas new order sales fell 8% to $16.7 million, as the new customer additions fell 3% to 233,000 due to lower advertising spending (down 10% to $7.8 million). However, the cost to acquire a new customer fell 8% to $33 from $36 in the year-ago quarter.  PetMed also notified that the average order size for the quarter fell to $78 from $81 in the prior-year quarter due to customers purchasing smaller quantities of products.  Gross profit increased 4% driven by increase in net sales, partially ...

Eli Lilly Beats, Raises Guidance – Analyst Blog

Zacks Market Commentaries (October 21st, 2009) Writes:
This morning, Eli Lilly & Co. (LLY) reported strong third quarter financials. The company’s earnings per share of $1.20 surpassed the Zacks Consensus Estimate of $1.02 and 98 cents reported in the year-ago period. Revenues recorded a 7% year on year increase to $5.56 billion, driven by an increase in both volume and prices, partially offset by unfavorable impact of foreign exchange. Of total revenues, while product sales were $5.4 billion (an increase of 6%), collaboration and other revenues accounted for the remaining $176.5 million (an increase of 51%), primarily due to the inclusion of Erbitux revenue as a result of the ImClone acquisition. The company’s other products recorded robust growth during the quarter compared to the year-ago period – Zyprexa (3% growth to $1.2 billion), Cymbalta (10% growth to $790.2 million), Humalog (16% growth to $500 million), Alimta (47% growth to $462 million). The ...

Big Lots Surpasses Expectations – Analyst Blog

Zacks Market Commentaries (August 25th, 2009) Writes:
Big Lots Inc. (BIG) recently reported better-than-expected second quarter results surpassing the bottom-line expectation. Effective cost management drove the growth in bottom-line with increased efficiencies in distribution and transportation costs, reduced advertising expenses, and decline in payroll costs.   Earnings per share (excluding one-time items) of 35 cents was well above the company’s guidance range of 26 cents to 32 cents, and surpassed the Zacks Consensus Estimate of 31 cents. Earnings per share increased 9.4% year over year, compared to 32 cents in the prior-year quarter.   On a reported basis, Big Lots delivered EPS of 34 cents, up 6.3%.   Management now expects EPS for the third and fourth quarter to be in the range of 14 cents to 19 cents, and 99 cents to $1.04, respectively. Management also raised its full year earnings guidance on account of better-than-expected results. It now expects EPS to be in ...

Bed Bath & Beyond Beats – Analyst Blog

Zacks Market Commentaries (June 26th, 2009) Writes:
Bed Bath & Beyond Inc. Beats Consensus Estimates, Shares RiseOn June 24, Bed Bath & Beyond, Inc. (BBBY) released earnings results for the first quarter ended May 30, 2009.The company performed above expectations. It reported a net income of $87.2 million or $0.34 per share, compared to $76.8 million or $0.30 per share the same quarter a year ago, thus beating the consensus EPS estimate by 9 cents. The company has beaten consensus estimates in each of the last three quarters.Net sales rose by 2.8% to $1.69 billion, up from $1.65 billion, which again was slightly above the consensus estimate of $1.68 billion. However, same-store sales declined by a less-than-expected 1.6%. Same-store sales have declined in five of the past six quarters, after having risen every quarter since the company went public ...

Things Turning Around at Rick’s Cabaret: It’s Time To Buy

Bullish Bankers (June 16th, 2009) Writes:

Rick’s Cabaret LogoOur favorite purveyor of adult fantasy, Rick’s Cabaret International (NASDAQ: RICK) reported results May 12th, and there appears to be good news on the horizon.

I am recommending immediate purchase of shares in Rick’s stock at or around $6-7 per share, and in fact I added to my position at $6.90 on May 13th.

Readers of my Twitter feed were able to take advantage of my real-time buy alert as well as a weak stock market to grab shares of Rick’s at a fantastic price, as the company’s results while not stellar, show marked improvement and portend greater things ahead.

As I wrote in my recent buy recommendation for Rick’s shares, I feel that the company has reached an inflection point

While the economy still shows signs of weakness, it appears that as a result of

...

Newsletter

No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.